Products for Research Use Only

BMS-986142

CAT: 0013-GTR19163691-01Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19163691-01Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BMS-986142 (BMS 986142) is a potent, selective and reversible BTK inhibitor with IC50 of 0.5 nM; displays 20-60-fold selectivity over Tec family kinases, >10,000-fold selectivity over JAK2; potently inhibits signaling and functional end points, including calcium flux (IC50=9 nM), production of cytokines, proliferation, and surface expression of CD86 (IC50=3-4 nM) ; potently inhibits BCR-stimulated expression of CD69 on B cells in human whole blood with IC50 of 90 nM; exhibits excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile.Rheumatoid Arthritis Phase 2 Clinical (In Vitro) :BMS-986142 potently inhibits human recombinant BTK with an IC50 of 0.5 nM in enzymatic assays. Against a panel of 384 kinases, BMS-986142 is highly selective, with only five other kinases (Tec, ITK, BLK, Txk, BMX) inhibited with 10,000 nM for both) . When Ramos B cells are treated with anti-IgM to activate BCR, BMS-986142 inhibits BTK-dependent calcium flux with an IC50 of 9 nM. (In Vivo) :BMS-986142 at 4, 10, and 30 mg/kg results in dose-dependent reductions of 26%, 43%, and 79% in clinically evident disease, respectively, at the end of the study. Interestingly, 4 mg/kg BMS-986142 provides an additive benefit in clinical scores (54% inhibition) when co-administered with MTX versus 19% inhibition with MTX alone. Co-administration of BMS-986142 at 4 mg/kg with MTX result in a 53% reduction in inflammation and bone resorption compared with 24% and 10%, respectively, with either drug alone. Furthermore, serum anti-collagen II IgG titers are significantly inhibited with 10 and 30 mg/kg BMS-986142. BMS-986142 also produces dose-dependent reductions in clinical scores when administration is delayed until the collagen booster on day 21. BMS-986142 doses of 2, 4, and 25 mg/kg in this therapeutic dosing regimen result in clinical score reductions of 17%, 37%, and 67%, respectively, at the end of the study.
CAS Number
1643368-58-4
Product Name Alternative
BMS 986142 | BMS986142
Purity
>98% (HPLC)
Solubility
DMSO: 120 mg/mL; Water: Insoluble (< 1 mg/ml refers to the product slightly soluble or insoluble)
Smiles
O=C (C1=CC (F) =[C@] ([C@]2=CC=CC (N3C (N (C) C4=C (C=CC=C4F) C3=O) =O) =C2C) C5=C1NC6=C5CC[C@H] (C (C) (O) C) C6) N
Molecular Formula
C32H30F2N4O4
Molecular Weight
572.613
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
6-Fluoro-5- (R) - (3- (S) - (8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3 (4H) -yl) -2-methylphenyl) -2- (S) - (2-hydroxypropan-2-yl) -2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide